**Boaz Hirshberg, MD, MBA**

Boaz Hirshberg, MD, MBA, joined Regeneron in 2021 and serves as Senior Vice President, Clinical Development Unit Head, Internal Medicine. Leading strategic program direction as well as early and late-stage clinical development for a broad range of therapeutic areas including ophthalmology, immunology, inflammation, infectious, cardiovascular, metabolic and rare diseases.

Boaz joined Regeneron in April 2021 from BOL Pharma, where he served as Executive Vice President, Chief Medical Officer. He also co-founded Regio Biosciences, a biotech company dedicated to the development of novel therapies to reduce plaque in the peripheral arteries and heart for the treatment of atherosclerosis.

Prior to BOL, Boaz spent twelve years at AstraZeneca/MedImmune in roles of increasing responsibility, most recently as Vice President, Clinical Therapeutic Area Head for Cardiovascular Renal and Metabolism (CVRM) at Medimmune. He built the CVRM clinical team from the ground up, establishing a group of more than fifty research physicians, clinical scientists, and operations team members, responsible for a pipeline that spanned cardiovascular, diabetes, obesity, NASH and renal diseases. He oversaw multiple international programs, ultimately moving eight into the clinic with several moving through development into Phase 2 trials. As a global clinical lead for the Onglyza® franchise, Boaz was accountable for delivering the SAVOR outcomes study, multiple global submissions as well as the NDA’s for Kombiglyze®XR and Qtern®. Prior to his roles at AstraZeneca, Boaz spent three years at Pfizer as Early Clinical Lead for diabetes.

Boaz completed his undergraduate and Medical Degrees at the Hebrew University and is Board certified in internal medicine, following his residency at the Hadassah Medical Center in Jerusalem. Boaz completed an endocrine fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases and received his MBA in Health Care Administration from Wilmington University.